5 the flanking spacer, as found previously with other type II-C systems 5 ( Supplementary Fig. 2a ). The 147 predicted transcriptional start site would yield a crRNA with a 24-nt spacer, similar to N. meningitidis Unlike H. parainfluenzae DSM 8978, the CRISPR-cas locus of S. muelleri ATCC 29453 152 appeared to be degenerate ( Supplementary Fig. 2a ). There is no apparent cas1 ORF, and the cas2
153
ORF lacks a canonical ATG start codon. However, the cas9 ORF (1,065aa) is intact and has all the 154 predicted functional domains found in other Cas9 orthologs, which suggested that SmuCas9 itself 155 might be active. When we attempted to define an appropriate guide RNA scaffold for SmuCas9, we 156 could not predict its tracrRNA (based in part on crRNA complementarity) from nearby genomic gaps in the genome assembly, we could not detect a tracrRNA sequence. As an alternative, we took 160 advantage of the non-orthogonality of sgRNAs from closely related Cas9 orthologs 28, 29 and used the 161 NmeCas9 sgRNA to test the cleavage activity of SmuCas9.
162
To define the PAM requirements for HpaCas9 and SmuCas9, a library of short DNA 163 fragments containing a unique protospacer and 10-nt randomized PAM sequences was subjected to in 164 vitro digestion using purified, recombinant Cas9 proteins and T7-transcribed sgRNAs. Next, digested 165 products were gel-purified and deep-sequenced. PAM sequences were identified from the resulting 166 sequencing data based on the frequency of nucleotides at each position of the digested products.
167
HpaCas9 had strong preference for 5'-N4GATT-3' PAM sequence (Fig. 2b) . Notably, this PAM is 168 similar to the consensus PAM sequence of NmeCas9 27, 28, [30] [31] [32] . We extracted spacer sequences from 169 the H. parainfluenzae 146_HPAR CRISPR locus and identified two candidate protospacers. When we 170 aligned the nucleotide sequences adjacent to the protospacers, we noted that both contained a 5'-6 analyses show that these Acrs can inactivate their cognate Cas9 proteins (Fig. 2c) . Given that some type II Acrs can inhibit orthologous Cas9 within the same subtype 17, 18, 33 , we tested Neisseria 185 representatives of the three other type II-C Acr families (AcrIIC1Nme, AcrIIC2Nme, and AcrIIC3Nme) for 186 inhibition of these two newly characterized Cas9 proteins. We found that all three of these previously To further characterize the physical interactions of AcrIIC4Hpa and AcrIIC5Smu with HpaCas9
189
and SmuCas9, we co-expressed each 6xHis-tagged Cas9 together with untagged Acr proteins in E.
190
coli. Using Ni 2+ -affinity chromatography, we determined that AcrIIC4Hpa directly bound HpaCas9 and 191 SmuCas9 (Fig. 3a) . This is similar to the results observed for the previously characterized type II-C
192
Acrs, which are known to bind to NmeCas9 19, 33 . By contrast, AcrIIC5Smu did not co-purify with any of 193 the tested Cas9 proteins under these conditions (Fig. 3a) .
194
Previous work has shown that some Acrs, such as AcrIIC1 family members, inhibit Cas9s
195
from Campylobacter jejuni (CjeCas9) and Geobacillus stearothermophilus (GeoCas9), in addition to
196
NmeCas9 34 . CjeCas9 shares 32% sequence identity with NmeCas9, and GeoCas9 shares 39%
197
(Supplementary Table 2 ). To determine the range of activity of AcrIIC4Hpa and AcrIIC5Smu, we tested 198 their inhibitory effects on type II-C Cas9s that have been validated for mammalian genome editing
199
( Supplementary Fig. 2c ). Despite the abilities of both AcrIIC4Hpa and AcrIIC5Smu to inhibit DNA
200
cleavage by NmeCas9 in vitro, neither prevented target DNA cleavage by CjeCas9 or GeoCas9.
201
To confirm these in vitro results, we also performed E. coli-based phage targeting assays to 202 assess the ability of AcrIIC4Hpa and AcrIIC5Smu to inhibit the activity of the various Cas9 orthologs. In 203 this assay, Cas9 expressed from a plasmid in E. coli with an sgRNA that targets phage Mu led to a 204 reduction in phage titer of ~10 6 plaque-forming units (pfu)/mL (Fig. 3b) . AcrIIC4Hpa expression 205 completely inhibited the activity of HpaCas9 and decreased the activity of NmeCas9 by ~100-fold
206
( Fig. 3b and Supplementary Fig. 3 ). Similarly, AcrIIC5Smu completely inhibited the activity of both
207
NmeCas9 and HpaCas9 (Fig. 3b) , allowing phage Mu to plaque robustly. We were unable to test (Fig. 3a) can also be detected in lysates from mammalian cells ( Supplementary Fig. 4a ). Consistent with AcrIIC5Smu inhibition of NmeCas9 DNA cleavage activity in editing, we co-transfected HEK293T cells transiently with plasmids expressing anti-CRISPR protein, 4a). In contrast, they had no effect on genome editing at the same genomic sites by SpyCas9, which 230 belongs to the type II-A CRISPR-Cas subtype and is very distantly related to NmeCas9 (Fig. 4a) . 
237
We previously noted a discrepancy in the potency of AcrIIC3Nme, which was least active in 
243
showing the highest protein signal at steady state ( Supplementary Fig. 4d ). To bypass the difference in 244 protein abundance, we delivered a preformed ribonucleoprotein (RNP) complex of NmeCas9, 245 sgRNA, and each Acr to HEK293T cells by electroporation. Then, we confirmed genome editing 246 inhibition by AcrIIC4Hpa and AcrIIC5Smu using tracking of indels by decomposition (TIDE) analysis 35 247 (Fig. 4b) . Acrs still displayed variations in activities even with RNP delivery, suggesting differences in 248 protein stability, off-rate, or other intrinsic properties. Of note, however, AcrIIC4Hpa and AcrIIC5Smu 249 consistently exhibited strong inhibitory potency both in vitro and in cultured cells (Fig. 1b and Fig. 4 ).
250
Furthermore, AcrIIC4Hpa and AcrIIC5Smu co-expression increased the steady-state accumulation of 251 NmeCas9 (with or without sgRNA co-expression), consistent with the possibility of a stabilizing 252 physical interaction (Supplementary Fig. 4e ). Overall, these data demonstrate that the two new anti-8 Once we confirmed the anti-CRISPR inhibition of sgRNA-guided NmeCas9 DNA cleavage in vitro 257 ( Fig. 1 ) and genome editing in cells (Fig. 4) effect on telomeric foci formed by dNmeCas9-(sfGFP)3 and dSpyCas9-(mCherry)3, as seen previously 1 ; 299 however, co-expression of AcrIIC4Hpa or AcrIIC5Smu resulted in loss of green foci formation by 300 dNmeCas9-(sfGFP)3 without abolishing the red telomeric foci formed by dSpyCas9-(mCherry)3 (Fig.   301 5c). We then quantified the number of cells exhibiting telomeric dNmeCas9-(sfGFP)3 foci in a blinded 302 experimental setup (Supplementary Fig. 5b ). We observed dNmeCas9-(sfGFP)3 foci in approximately 303 80% of cells in the absence of any Acr protein, in 70% of cells expressing AcrE2 protein (negative 304 control), and in 0% of cells in the presence of AcrIIC3Nme (as a positive control 1, 19 ). We found that 0%
305
of cells exhibited dNmeCas9-(sfGFP)3 telomeric foci when the two novel anti-CRISPRs were co-306 expressed (0 out of 78 for AcrIIC4Hpa, and 0 out of 82 for AcrIIC5Smu) ( Supplementary Fig. 5b ). These
Discussion

330
The prevalence of CRISPR-Cas immune systems in bacteria and archaea has driven phages to evolve anti-CRISPR proteins. Indeed, numerous anti-CRISPRs against type I and type II systems have been parainfluenzae and S. muelleri. We define PAMs for the newly characterized HpaCas9 and SmuCas9
336
orthologs and show that they are functional in vitro and that HpaCas9 confers phage immunity in 337 bacteria, expanding the functional Cas9 repertoire. These additional anti-CRISPRs and Cas9s total 338 five anti-CRISPR families that differentially inactivate five different type II-C Cas9 orthologs (Fig. 6 ).
as CRISPR interference activity in bacteria, and both also prevent NmeCas9-mediated genome found to be specific to closely related Cas9 orthologs, as they did not inhibit the more distantly related each anti-CRISPR's breadth of inhibition as broad-spectrum or highly specific, with gradations 348 between these two extremes. For example, the AcrIIC1 family of Acrs can inhibit multiple Cas9s, 
361
Separately, AcrIIA families were shown to prevent a gene-drive propagation in Saccharomyces cerevisiae 42 .
362
These are a few examples of the potential utility of Acrs as Cas9 off-switches. Many applications stand 363 to benefit from increasing the numbers, specificities, and inhibitory mechanisms of anti-CRISPRs, for could be used to control multiple Cas9s simultaneously, or specific Cas9s but not others, upstream or downstream of target recognition, to achieve maximal flexibility of both genome manipulation and 368 regulation.
7953) was obtained from Addgene (#87700) and similarly cloned into the pMCSG7 vector. To make 13 lysed by sonication and the supernatant was then clarified by centrifugation at 18000 rpm for 30 min.
441
The supernatant was incubated with pre-equilibrated Ni-NTA agarose (Qiagen) for 1 hr. The resin imidazole, 1 mM DTT]. The proteins were eluted in Elution buffer containing 300 mM imidazole.
For Acr proteins, the 6xHis tag was removed by incubation with His-tagged Tobacco Etch Virus
445
(TEV) protease overnight at 4 °C followed by a second round of Ni-NTA purification to isolate 446 successfully cleaved, untagged anti-CRISPRs (by collecting the unbound fraction). Cas9s were further 447 purified using cation exchange chromatography using a Sepharose HiTrap column (GE Life 448 Sciences). Size exclusion chromatography was used to purify NmeCas9 further in 20 mM HEPES-449 KOH (pH 7.5), 300 mM KCl and 1 mM TCEP.
451
In vitro DNA cleavage
452
For the in vitro DNA cleavage experiments with NmeCas9 ( Fig. 1C and Supplementary Fig. 1 
